These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 37339636)

  • 41. Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes.
    Sison SL; Vermilyea SC; Emborg ME; Ebert AD
    Curr Neurol Neurosci Rep; 2018 Oct; 18(12):84. PubMed ID: 30284665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
    Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
    Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chromatin-Bound Oxidized α-Synuclein Causes Strand Breaks in Neuronal Genomes in in vitro Models of Parkinson's Disease.
    Vasquez V; Mitra J; Hegde PM; Pandey A; Sengupta S; Mitra S; Rao KS; Hegde ML
    J Alzheimers Dis; 2017; 60(s1):S133-S150. PubMed ID: 28731447
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
    Sahay S; Ghosh D; Singh PK; Maji SK
    Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
    [TBL] [Abstract][Full Text] [Related]  

  • 45. C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease.
    McGlinchey RP; Lacy SM; Huffer KE; Tayebi N; Sidransky E; Lee JC
    J Biol Chem; 2019 Jun; 294(25):9973-9984. PubMed ID: 31092553
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype.
    Faustini G; Longhena F; Masato A; Bassareo V; Frau R; Klingstedt T; Shirani H; Brembati V; Parrella E; Vezzoli M; Nilsson KPR; Pizzi M; Spillantini MG; Bubacco L; Bellucci A
    Mol Ther; 2022 Apr; 30(4):1465-1483. PubMed ID: 35038583
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Organoid and pluripotent stem cells in Parkinson's disease modeling: an expert view on their value to drug discovery.
    Marotta N; Kim S; Krainc D
    Expert Opin Drug Discov; 2020 Apr; 15(4):427-441. PubMed ID: 31899983
    [No Abstract]   [Full Text] [Related]  

  • 48. LRP1 is a neuronal receptor for α-synuclein uptake and spread.
    Chen K; Martens YA; Meneses A; Ryu DH; Lu W; Raulin AC; Li F; Zhao J; Chen Y; Jin Y; Linares C; Goodwin M; Li Y; Liu CC; Kanekiyo T; Holtzman DM; Golde TE; Bu G; Zhao N
    Mol Neurodegener; 2022 Sep; 17(1):57. PubMed ID: 36056345
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
    Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
    J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. α-mangostin derivative 4e as a PDE4 inhibitor promote proteasomal degradation of alpha-synuclein in Parkinson's disease models through PKA activation.
    Chen JY; Zhu Q; Cai CZ; Luo HB; Lu JH
    Phytomedicine; 2022 Jul; 101():154125. PubMed ID: 35525236
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils.
    Patterson JR; Duffy MF; Kemp CJ; Howe JW; Collier TJ; Stoll AC; Miller KM; Patel P; Levine N; Moore DJ; Luk KC; Fleming SM; Kanaan NM; Paumier KL; El-Agnaf OMA; Sortwell CE
    Neurobiol Dis; 2019 Oct; 130():104525. PubMed ID: 31276792
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neuroinflammatory gene expression profiles of reactive glia in the substantia nigra suggest a multidimensional immune response to alpha synuclein inclusions.
    Stoll AC; Kemp CJ; Patterson JR; Howe JW; Steece-Collier K; Luk KC; Sortwell CE; Benskey MJ
    Neurobiol Dis; 2024 Feb; 191():106411. PubMed ID: 38228253
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Distinct alpha-Synuclein species induced by seeding are selectively cleared by the Lysosome or the Proteasome in neuronally differentiated SH-SY5Y cells.
    Pantazopoulou M; Brembati V; Kanellidi A; Bousset L; Melki R; Stefanis L
    J Neurochem; 2021 Mar; 156(6):880-896. PubMed ID: 32869336
    [TBL] [Abstract][Full Text] [Related]  

  • 54. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
    Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adenosine A1 receptor ligands bind to α-synuclein: implications for α-synuclein misfolding and α-synucleinopathy in Parkinson's disease.
    Jakova E; Moutaoufik MT; Lee JS; Babu M; Cayabyab FS
    Transl Neurodegener; 2022 Feb; 11(1):9. PubMed ID: 35139916
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Leveraging the preformed fibril model to distinguish between alpha-synuclein inclusion- and nigrostriatal degeneration-associated immunogenicity.
    Stoll AC; Sortwell CE
    Neurobiol Dis; 2022 Sep; 171():105804. PubMed ID: 35764290
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alpha-Synuclein: The Interplay of Pathology, Neuroinflammation, and Environmental Factors in Parkinson's Disease.
    He S; Zhong S; Liu G; Yang J
    Neurodegener Dis; 2020; 20(2-3):55-64. PubMed ID: 33465773
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hypoxic stress accelerates the propagation of pathological alpha-synuclein and degeneration of dopaminergic neurons.
    Guo M; Liu W; Luo H; Shao Q; Li Y; Gu Y; Guan Y; Ma W; Chen M; Yang H; Ji X; Liu J
    CNS Neurosci Ther; 2023 Feb; 29(2):544-558. PubMed ID: 36514210
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.
    Fares MB; Ait-Bouziad N; Dikiy I; Mbefo MK; Jovičić A; Kiely A; Holton JL; Lee SJ; Gitler AD; Eliezer D; Lashuel HA
    Hum Mol Genet; 2014 Sep; 23(17):4491-509. PubMed ID: 24728187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
    Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
    J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.